Search clinical trials for: Canakinumab

Total 96 results

Novartis Pharmaceuticals

Completed

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Hereditary Periodic Fevers | Systemic Juvenile Idiopathic Arthritis

France
Novartis Pharmaceuticals

Completed

Canakinumab in Patients With Active Hyper-IgD Syndrome

Mevalonate Kinase Deficiency

Spain
Novartis Pharmaceuticals

Completed

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement (Behcet)

Behcet Disease

Turkey
Rabin Medical Center

Unknown

Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)

Periodic Fever

Israel
University Hospital, Basel, Switzerland

Terminated

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (CONVERT-AF)

Atrial Fibrillation

Switzerland, Germany
Charite University, Berlin, Germany
Novartis Pharmaceuticals

Completed

Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses (ILUVIT)

Vasculitis | Urticaria

Germany
Novartis

Completed

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
John Mascarenhas

Recruiting

Study of Canakinumab in Patients With Myelofibrosis

Primary Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | ET-MF | Post-polycythemia Vera Related Myelofibrosis | PV-MF

United States
Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization

Completed

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. (β-SPECIFIC 3)

Systemic Juvenile Idiopathic Arthritis

Italy, United States, Belgium, Germany, Greece, Russian Federation, Turkey, Spain, France, Israel, Canada, Hungary, Switzerland, United Kingdom, Brazil, Austria, Sweden, Netherlands, Argentina, Peru, Poland
PD Dr. med. Stephan Michels
Novartis; University Hospital, Zürich

Terminated

A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP) (ILARIS)

Proliferative Diabetic Retinopathy

Switzerland
Charite University, Berlin, Germany

Terminated

Canakinumab for Treatment of Adult-onset Still's Disease (CONSIDER)

Adult-Onset Still´s Disease

Germany
Charite University, Berlin, Germany
Novartis Pharmaceuticals

Completed

Ilaris® Effects in Schnitzler Syndrome (ILESCH) (ILESCH)

Schnitzler Syndrome

Germany
Novartis Pharmaceuticals
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest...

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 1)

Systemic Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Switzerland, Germany, United Kingdom, Israel, South Africa, Belgium, Greece, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru, Denmark
Radboud University Medical Center
Novartis

Completed

Efficacy and Safety of Canakinumab in Schnitzler Syndrome

Schnitzler Syndrome

Netherlands
Priscilla Hsue, MD
Massachusetts General Hospital

Completed

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Cardiovascular Disease | HIV

United States
Mario Negri Institute for Pharmacological Research
Novartis Pharmaceuticals

Terminated

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer (CANAL)

Lung Cancer

Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (CAN-COVID)

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Spain, United States, United Kingdom, Russian Federation, Italy, France
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Sickle Cell Anemia

Turkey, United States, Germany, Canada, United Kingdom, Israel, South Africa
Novartis Pharmaceuticals

No longer available

Canakinumab MAP in COVID-19 Pneumonia With CRS

Cytokine Release Syndrome in COVID-19-induced Pneumonia
Novartis Pharmaceuticals

Completed

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Diabetes Mellitus, Type 2 | Atherosclerosis | Prediabetic State

Germany, Israel, United States, Canada, United Kingdom
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Novartis Pharmaceuticals
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Terminated

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

NOMID | CINCA Syndrome

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Japan
University of Leipzig
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Myelodysplastic Syndromes | Anemia

Germany
Novartis Pharmaceuticals

Completed

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Cryopyrin Associated Periodic Syndrome

Canada
Novartis

Completed

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Switzerland, Germany, United States, Belgium, Italy, Netherlands, Spain, Turkey
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Kawasaki Disease
Novartis

Completed

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells Syndrome

United States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
Novartis Pharmaceuticals

Completed

Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms

NALP3 Mutation

United Kingdom, France, Germany, India, Spain
University of Zurich

Unknown

Efficacy Study of Canakinumab to Treat Urticaria (URTICANA)

Chronic Idiopathic Urticaria

Switzerland
University of Zurich

Completed

Canakinumab for Pyoderma Gangrenosum

Pyoderma Gangrenosum

Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Adult Onset Still's Disease

Japan
Novartis Pharmaceuticals

Active, not recruiting

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Systemic Juvenile Idiopathic Arthritis

Japan
Novartis Pharmaceuticals

Active, not recruiting

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Knee Osteoarthritis

United States, Hungary, Estonia, Poland, Czechia, Latvia
The Cleveland Clinic
Novartis

Completed

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

COVID-19 | SARS-CoV 2

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

Germany, United States, Netherlands
Novartis Pharmaceuticals

Completed

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Acute Gouty Arthritis

Germany, United States, Lithuania, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Hereditary Periodic Fevers

Belgium, Italy, Japan, Russian Federation, Turkey, Spain, Germany, United Kingdom, France, United States, Ireland, Israel, Canada, Hungary, Netherlands, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Familial Mediterranean Fever

Turkey
Novartis Pharmaceuticals

Terminated

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Peripheral Artery Disease

United States, Germany, Jordan
National Institute of Diabetes and Digestive and...

Completed

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes (TN14)

Type 1 Diabetes | Preservation of Insulin Secretion | Newly Diagnosed Type 1 Diabetes | Canakinumab in Type 1 Diabetes

United States, Canada
Novartis Pharmaceuticals

Terminated

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment

United States, Finland, United Kingdom, Iceland
Novartis

Completed

Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Spain, Turkey, Switzerland
Novartis Pharmaceuticals

Completed

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) (CONTROL FMF)

Colchicine Resistant/Intolerant Familial Mediterranean Fever

Israel
M.D. Anderson Cancer Center

Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Stage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
University Hospital, Basel, Switzerland

Recruiting

Canakinumab for the Treatment of Postprandial Hypoglycemia (CanpHy)

Postprandial Hypoglycemia

Switzerland

Search clinical trials for: Canakinumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations